Gallium-68 NOTA AE105

N/A

Report date: 2025/11/20 13:28:38
NME

Base Information

Drug NameGallium-68 NOTA AE105
Drug Alias Name68Ga-NOTA-Asp-Cha-Phe-Ser-Arg-Tyr- Leu-Trp-SeruTRACEuTREATCS-00168Ga-NOTA-AE105
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionUrokinase plasminogen activator surface receptor inhibitorsPositron-emission tomography enhancersIonising radiation emitters
TargetsUrokinase plasminogen activator surface receptor
Therapy Area/IndicationsBone metastasesHair DiseasesUrinary Bladder Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCurasight ApsRigshospitalet
China Registration ClassN/A

Develop Information

Active CompaniesCurium IncRigshospitaletApplied Biology Inc +[4] 
Inactive CompaniesN/A
Active IndicationsHair DiseasesGenital Neoplasms, FemaleHead and Neck Neoplasms +[4] 
Inactive IndicationsBone metastasesUrinary Bladder NeoplasmsProstatic Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A